Overview

• Global life sciences and diagnostics innovator's Q1 revenue rose 3.5%, meeting analyst expectations

• Adjusted EPS for Q1 grew 9.5% and beat analyst expectations

• Company, in Feb, had announced intention to acquire Masimo Corp, a provider of patient monitoring solutions

Outlook

• Danaher sees Q2 2026 non-GAAP core revenue up low-single digit percent year-over-year

• Company expects full-year 2026 non-GAAP core revenue growth of 3% to 6%

• Danaher raises full-year adjusted diluted EPS guidance to $8.35-$8.55 from $8.35-$8.50

Result Drivers

• BIOPROCESSING STRENGTH - Co said Bioprocessing segment delivered strong growth, supporting overall results

• LIFE SCIENCES OUTPERFORMANCE - Better-than-expected Life Sciences performance helped offset weakness in Diagnostics

• WEAK RESPIRATORY SEASON - Lighter-than-typical Q1 respiratory season at Cepheid weighed on Diagnostics segment

Company press release: ID:nPn7SDkxJa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Danaher Corp is $249.50, about 27.6% above its April 20 closing price of $195.50

• The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 27 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.